Related Experiment Videos
Suppression of various human tumor cell lines by a dominant negative H-ras mutant
1Laboratory of Molecular Genetics, Hokkaido University School of Medicine, Japan.
Abstract:
A dominant negative H-ras mutant, N116Y, was transfected into a variety of human tumor cell lines. N116Y extremely inhibited the proliferation of A431 (vulva), PC3 (prostate), T24 (bladder), MCF7 (breast), NKPS and TMK1 (stomach) cancer cell lines. A431 and PC3 cells were particularly susceptible to N116Y. In order to examine the effects of N116Y on the neoplastic phenotypes, we transfected a less efficient N116Y expression vector into A431 cells. Almost all clones survived after G418 selection. However, they did not retain the N116Y gene and only one clone faintly expressed N116Y. This N116Y-expressing clone had no tumorigenicity in vivo, and revealed deformed morphology and DNA fragmentation, suggesting that N116Y might have induced apoptotic cell death. Thus, N116Y may be applicable for gene therapy of a wide spectrum of human tumors.
Insights
A novel H-ras mutant, N116Y, effectively inhibited proliferation across multiple human cancer cell lines. This dominant-negative mutant shows promise for gene therapy, potentially inducing apoptotic cell death in tumors.
Area of Science:
- Oncology
- Molecular Biology
- Gene Therapy
Background:
- The H-ras oncogene plays a critical role in cell proliferation and cancer development.
- Dominant-negative mutants offer a potential strategy to counteract oncogenic signaling.
- Targeting H-ras signaling is a significant area of cancer research.
Purpose of the Study:
- To investigate the anti-proliferative effects of a dominant-negative H-ras mutant (N116Y) on various human tumor cell lines.
- To explore the potential of N116Y in inducing neoplastic cell death and its applicability in gene therapy.
Main Methods:
- Transfection of the dominant-negative H-ras mutant N116Y into human tumor cell lines (A431, PC3, T24, MCF7, NKPS, TMK1).
- Use of a less efficient N116Y expression vector in A431 cells to study neoplastic phenotypes.
- In vivo tumorigenicity assays and morphological/DNA fragmentation analysis of N116Y-expressing cells.
Main Results:
- N116Y significantly inhibited the proliferation of multiple human cancer cell lines, with A431 and PC3 cells being particularly sensitive.
- A431 clones expressing N116Y exhibited no in vivo tumorigenicity.
- N116Y expression induced morphological changes and DNA fragmentation, indicative of apoptotic cell death.
Conclusions:
- The dominant-negative H-ras mutant N116Y demonstrates potent anti-cancer activity against a broad range of human tumors.
- N116Y-induced apoptosis suggests its potential as a therapeutic agent for gene therapy in various cancers.